Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19

(E-pub Ahead of Print)

Author(s): Iago Dillion Lima Cavalcanti*, Sandrelli Meridiana de Fátima Ramos dos Santos Medeiros, Daniel Charles dos Santos Macêdo, Isabella Macário Ferro Cavalcanti, Mariane Cajubá de Britto Lira Nogueira

Journal Name: Current Drug Delivery

Become EABM
Become Reviewer

Abstract:

In response to the global outbreak caused by SARS-CoV-2, this article aims to propose the development of nanosystems for the delivery of hydroxychloroquine in the respiratory system to the treatment of COVID-19. Performed a descriptive literature review, using the descriptors "COVID-19", "Nanotechnology", "Respiratory Syndrome" and "Hydroxychloroquine", in the PubMed, ScienceDirect and SciElo databases. After analyzing the articles according to the inclusion and exclusion criteria, they were divided into 3 sessions: Coronavirus: definitions, classifications and epidemiology, pharmacological aspects of hydroxychloroquine and pharmaceutical nanotechnology in targeting of drugs. We used 131 articles published until July 18, 2020. Hydroxychloroquine seems to promote a reduction in viral load, in vivo studies, preventing the entry of SARS-CoV-2 into lung cells, and the safety of its administration is questioned due to the toxic effects that it can develop, such as retinopathy, hypoglycemia and even cardiotoxicity. Nanosystems for the delivery of drugs in the respiratory system may be a viable alternative for the administration of hydroxychloroquine, which may enhance the therapeutic effect of the drug with a consequent decrease in its toxicity, providing greater safety for implementation in the clinic in the treatment of COVID-19.

Keywords: SARS-CoV-2, COVID-19, Nanotechnology, Respiratory Syndrome, Hydroxychloroquine.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1567201817666200827110445
Price: $95

Article Metrics

PDF: 1